GlassScriptPhysician profile
Olga Varnacheva
NPI 1952815771
$876.24
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $631 · 2022: $245.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $179.54 | 2021-2022 | |
| Biotronik INC. | $74.25 | 2021 | |
| Janssen Pharmaceuticals, INC | $68.93 | 2021 | |
| Merck Sharp & Dohme LLC | $62.96 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.71 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $56.99 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $48.37 | 2021-2022 | |
| Amgen INC. | $45.27 | 2021 | |
| Abbvie INC. | $45.22 | 2021-2022 | |
| Lilly USA, LLC | $42.26 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $37.43 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.02 | 2022 | |
| Abbott Laboratories | $24.76 | 2022 | |
| Alnylam Pharmaceuticals INC. | $22.15 | 2021 | |
| Almatica Pharma LLC | $17.87 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $17.33 | 2021 | |
| Amarin Pharma, INC. | $16.05 | 2021 | |
| Opko Pharmaceuticals, LLC | $15.34 | 2021 | |
| Glaxosmithkline, LLC. | $13.79 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Varnacheva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.